Clinical trialNCT02943317TerminatedPhase 1Interventional

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

SponsorVerastem, Inc.Enrollment98Epithelial Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Hagop Youssoufian, MD
Verastem, Inc.
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Florida Cancer Specialists & Research Institute (fcs)
Sarasota, Florida, United States
Dana Farber Cancer Instiyute
Boston, Massachusetts, United States
Stephenson Cancer Center (university of Oklahoma)
Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States
Mary Crowley Cancer Research Centers
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Part A - AvelumabPart A - VS-6063

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2016
Primary completion: 28 Aug 2018
Completion: 28 Dec 2018
Last update posted: 30 Apr 2019
Registered enrollment: 98
Registry id: NCT02943317

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.